This Questions are from "Patent Law & Pharmaceutical IndustryPatent Law & Pharmaceutical Industry"

Question 5(4 points)

In the CardiAQ v. Neovasc case, CardiAQ, a heart valve developer, enlisted Neovasc to manufacture a prototype based on their designs and confidential information. Later, Neovasc developed and filed a patent for a remarkably similar heart valve, leading to a dispute over intellectual property rights. Which of the following best describes the core issue that led to the lawsuit?

Question 5 options:

	CardiAQ's negligence in securing a patent for their heart valve design prior to engaging Neovasc.
	Neovasc's independent invention of a new heart valve after ending their consultancy with CardiAQ.
	CardiAQ's unauthorized use of Neovasc's proprietary processes.
	Neovasc's use of CardiAQ's confidential information to develop a competing product.

Question 6(4 points)

Considering the principle of absolute novelty in patent law, suppose a pharmaceutical company claims a patent for a composition comprising a novel synthetic compound X, intended to treat cardiovascular diseases. Before filing the patent, the company had detailed the synthesis and potential therapeutic uses of compound X in an international journal. Which of the following would likely impact the patent's validity?

Question 6 options:

	The company's prior publication about compound X's synthesis and uses.
	The company's internal reports on compound X, not shared publicly.
	A presentation on compound X's theoretical benefits at a private industry meeting, without revealing its chemical structure.
	The company's filing for a patent in another country after the publication but within a 12-month priority window.

Question 7(5 points)

How might a pharmaceutical company utilize Inter Partes Review (IPR) as a strategy in conjunction with their district court litigation efforts?

Question 7 options:

	Focusing on IPR as a method to publicly disclose all proprietary information about their drugs, aiming to enhance industry transparency and customer trust, without linking it to district court litigation.
	Utilizing IPR solely to increase the duration of their own patent protection by requesting the PTAB to extend the term of their patents beyond the standard expiration date.
	By employing IPR to challenge the validity of a competitor's patent at the Patent Trial and Appeal Board (PTAB) as a defensive strategy to potentially invalidate patents that are subject to infringement litigation in district court.
	Engaging in IPR to directly negotiate lower licensing fees with competitors, without involving the PTAB or district court litigation processes.

Question 8(2 points)

Once a patent application has been filed, no one else can legally use the invention.

Question 8 options:

	True
	False

Question 9(2 points)

If I get a patent on an invention, then I don't have to worry about infringing someone else's patent

Question 9 options:

	True
	False

Question 10(2 points)

Any invention can be patented if no one else has yet filed for a patent on it

Question 10 options:

	True
	False